Kilroy Realty Corporation: A Value Investing Deep Dive

Is the revenue recurring, stable, and predictable? View: Relative to an "ordinary company," a REIT's rental income is fairly recurring. But relative to an "excellent consumer or software company," KRC's predictability is not high. The key variables for an office REIT are not "how many products sold" but occupancy, renewal rates, rent spreads, tenant improvement spending, development deliveries, and capital market conditions. In Q1 2026, KRC's second-generation office leasing, excluding short-term leases, saw GAAP rents fall 10.6% and cash rents fall 16.8%. Only after excluding long-vacant space empty for more than 12 months did GAAP and cash rents grow 19.2% and 5.2% respectively. This shows that pricing power is not broad-based but sharply tiered.

What is the cost structure? Fact: A REIT has no "gross cost" in the traditional manufacturing sense; NOI is the better lens. KRC's total property NOI in 2025 was $736.2 million, for an NOI margin of about 66.2%. Above NOI, however, it must carry general and administrative, leasing, interest, tenant improvement, and development costs. Interest expense in 2025 was $126.3 million, capital spending on operating properties and other capital assets was $116.0 million, and development, redevelopment, and land spending was $174.7 million. This is a high-cash-flow but also high-capital-intensity model.

Does it depend on a few customers, suppliers, channels, policies, or key individuals? Fact: From the materials reviewed, I can confirm the business model does not depend on a single supplier or distribution channel. But the latest top-ten-tenant revenue concentration and single-large-tenant lease expiry exposure are not fully laid out in the materials obtained this time, and this remains information to be supplemented. Inference: As an owner of high-end office and lab properties on the West Coast, KRC's economics depend heavily on the expansion and financing environment of office users in technology, life science, legal, and professional services. Its "customer concentration risk" is therefore more a combined risk of industry and regional concentration than a single-customer risk.

Is the business simple, transparent, and easy to understand? Would I hold it if the stock market closed for five years? View: The business model itself is not complex—buy land, develop, lease, refinance, pay dividends—so it "can be understood." But the key variables driving returns are many, and most are tied to the macro environment, regional supply and demand, and capital markets, so it is not a business "simple enough to safely ignore." Would I hold it if the market closed for five years? At a lower price, yes; at the current price, not comfortably. I would happily own some of its quality assets, but I would not ignore the industry's structural change and capital-spending pressure. Business comprehensibility score: 4/5.

Industry and competitive landscape Fact: The U.S. office market showed some signs of stabilizing in Q1 2026: national net absorption was 6.9 million square feet, the strongest first quarter since 2020; overall vacancy fell to 18.6%, and prime office vacancy fell to 12.7%. But the life science lab market remained soft: lab vacancy across the top 13 U.S. markets rose to 23.2%, San Francisco Bay Area life science vacancy was about 30.7%, San Francisco office vacancy about 30.4%, San Francisco Peninsula office vacancy about 24.9%, and Puget Sound about 28.3%. Austin and San Diego improved but are still early in recovery.

Inference: For KRC this means the industry is in a phase of "differentiated cyclical repair" rather than a clear high-growth boom. High-quality, green, transit-accessible properties that meet the needs of innovative companies may recover first; ordinary office buildings and oversupplied lab space stay under pressure. KRC benefits from the "flight to quality" but is constrained by its regional concentration.

Who are the main competitors, and what is the company's position? Fact: In the public market, KRC is often compared with office and life science REITs such as BXP, ARE, HIW, and VNO. KRC's current market cap of roughly $3.97 billion is clearly smaller than BXP's roughly $9.33 billion and ARE's roughly $7.99 billion, and larger than HIW's roughly $2.82 billion. In Q1 2026, its stabilized portfolio occupancy by region was: San Francisco Bay Area 75.2%, Los Angeles 74.8%, Seattle 79.3%, San Diego 84.6%, and Austin 83.2%. It is not the "scale king" of the industry, but it has a meaningful presence in West Coast innovation submarkets.

Is this a "good company in a good industry" or an "excellent company in a bad industry"? View: Closer to a "relatively excellent company in a bad industry." Its strengths are asset quality, development capability, and land scarcity; its weaknesses are industry supply and demand, remote work, and capital intensity, none of which the company can control on its own. Industry attractiveness score: 2/5.

Moat and Management

Where does the moat actually come from? Fact: KRC's most convincing moat lies not in brand, network effects, or data, but in scarce locations + high-quality assets + development and operating capability + green/sustainability certification + tenant relationships. At the end of 2025, 70% of the stabilized portfolio was LEED-certified, of which 94% was Gold or Platinum level; the company has run its investment portfolio at operational carbon neutrality since 2020. For large tenants that need to draw employees back to the office and that value ESG and building quality, this does form real differentiation.

But how strong are these moats? View: They exist, but they are not deep. Brand advantage: weak, since tenants lease a building, not a consumer brand. Cost advantage: limited, as high-end assets often mean higher capital spending instead. Scale advantage: moderate-to-weak, since KRC is not the largest office REIT. Network effects: almost none. Switching costs: moderate, as lab relocation and headquarters moves are costly but not irreversible. Channel advantage: weak. Licensing/regulatory barriers: moderate, as permitting, land, and development experience in core submarkets form a barrier. Culture and operations: moderate; on asset quality, sustainable operation, and project execution, KRC is above the industry's mediocre norm. Capital allocation capability: has bright spots but still to be proven.

Is the moat widening, stable, or narrowing? Inference: Overall it is "stable at the asset level, narrowing at the industry level." At the asset level, AI and high-quality office demand have brought some marginal improvement to San Francisco; CBRE estimates AI-related companies could absorb as much as 16 million square feet of San Francisco office demand by 2030, and San Francisco office net absorption turned clearly positive in Q1 2026. At the industry level, life science lab rents and absorption remain weak, with the Bay Area and San Diego both facing high vacancy; KRC's own overall occupancy in Q1 2026 was still below 80%, showing that the moat has not yet translated into overwhelming pricing power.

Can the company raise prices through inflation? Can it stay profitable in a downturn? Were past high margins structural or cyclical? View: With quality assets, prime locations, and controlled supply, it can raise prices partially, but at present the company has not fully regained pricing power across the board. The most direct evidence is that second-generation lease cash rents were still negative overall in Q1 2026. In a downturn, the company can keep operating thanks to long-term leases, cash flow, and asset disposition capability, but GAAP earnings, dividend safety, and intrinsic value would all be pressured. Its past high margins blended a structural premium from quality assets with an evident cyclical premium from the low-rate era and disposition gains.

Moat strength score: 3/5. Note, however, that this 3 is not a "consumer-staples-leader 3." It is "a relative-advantage 3 earned through quality assets in a difficult industry."

Is management trustworthy, and is capital allocation rational? Fact: Current CEO Angela M. Aman has served as CEO and director since January 2024, after serving as CFO/President at Brixmor. The proxy statement shows that as of March 1, 2026, Angela Aman held roughly 76,770 shares, and all directors and officers combined held roughly 977,000 shares, or 0.83%. Management interests are aligned with shareholders, but this is not a "heavily invested" stake.

Fact: On compensation, about 87.4% of the CEO's target total compensation in 2025 was performance- and stock-price-linked "at risk" pay; three-quarters of the 2025 long-term equity awards carried performance vesting conditions, with metrics including relative TSR and average net debt/EBITDAre. The 2026 compensation framework continues to include FFO, executed leasing square footage, and liquidity ratios, and strengthens three-year measurement. At a minimum, this design shows the board has not entirely ignored leverage and shareholder returns.

Fact + View: On capital allocation, in Q1 2026 the company sold roughly $145.5 million of non-core properties, and in April it completed the sale of two Los Angeles residential towers, bringing year-to-date non-core asset sales to roughly $350 million. Over the same period, the company repurchased about 2.4 million shares at an average price of $30.80 per share for $72.7 million, and in April it repaid $50 million of private placement notes due in 2026. For a REIT trading below book value with the industry still mid-downturn, "selling non-core assets, paying down debt, buying back modestly at low prices, and prudently advancing highly pre-leased projects" is capital allocation I am willing to view positively. The new CEO's tenure is simply still too short to merit a higher score.

Management and capital allocation score: 3/5. Not because I think management is poor, but because: rational actions have appeared, but the time sample is not yet long enough, and insider ownership is not especially heavy.

Financial Quality

To state the conclusion first: KRC's cash flow quality is better than its industry label suggests, but its return on capital is far below the "excellent company" standard. From 2021 to 2025, revenue stayed roughly in the $955 million–$1.136 billion range and operating cash flow in the $516 million–$603 million range, showing the underlying rent machine is still working. But declining occupancy, development capital spending, rent divergence, and volatile disposition gains have made per-share intrinsic value growth anything but smooth.

The table below uses GAAP revenue/net income, along with operating cash flow, debt, and cash, which can be verified directly or derived directly from the annual reports. For a REIT, "gross margin" does not apply, so I substitute NOI margin. Some ratios are my approximate estimates, noted after the table.

Notes: Fact: 2025 revenue was $1.113 billion, net income to common $276 million, operating cash flow $566 million, and operating-property capex $116 million; the 2024 figures were $1.136 billion / $211 million / $541 million / $100 million; the 2023 figures were $1.130 billion / $212 million / $603 million / $97 million. The 2021–2022 revenue, net income, operating cash flow, debt, and cash come from the 2021/2023 annual reports; the 2021–2022 operating-property capex is not fully laid out in the materials obtained this time, hence "to be supplemented." The approximate net debt/EBITDA and interest coverage are values I derived from the annual reports' EBIT, D&A, interest expense, and cash.

Are profits real cash profits or accounting profits? View: From 2023 to 2025, cash profit clearly exceeds GAAP net income. This does not necessarily mean the company is "super excellent"; it is because a REIT's depreciation and amortization is large, while tenant improvements, leasing commissions, and development spending eat some of that "book cash" back. So the most reasonable statement is not that "net income is distorted," but that: GAAP net income understates the recurring cash generation of stabilized assets, yet cannot overstate development expansion into a free lunch.

Does growth require heavy capital investment? Does the company make more money as it grows, or run shorter of cash as it grows? Fact: From 2023 to 2025, development, redevelopment, and land spending was roughly $446 million, $366 million, and $175 million; capital spending on operating properties and other capital assets was roughly $97 million, $100 million, and $116 million. View: KRC's stabilized portfolio does spit out cash, but corporate growth is by no means asset-light. If growth is driven by new development, the company will lean clearly more on retained internal cash, asset dispositions, and the financing environment. In other words, this is not a business model where "growth gets easier."

Is the balance sheet sound? Fact: At the end of 2025, total assets were $10.915 billion, shareholders' equity $5.421 billion, and net debt (roughly total debt net of cash, equivalents, and marketable securities) about $4.38 billion; about 95.7% of debt was contractually fixed-rate. The year-end 2025 debt maturity schedule shows roughly $601 million maturing in 2026, followed by $249 million in 2027, $400 million in 2028, $475 million in 2029, and $500 million in 2030. In April 2026, the company repaid $50 million of the 2026 maturities.

View: This is not a "fragile, about-to-break" balance sheet, but it is by no means one that lets me ignore industry risk. Most debt being fixed-rate is a plus, but net debt/EBITDA above 6x and interest coverage of only around 2–3x mean the company must rely on continued leasing, prudent capital spending, and asset dispositions to preserve room to maneuver. It can survive, but it has no luxurious margin for error.

Share count, dividend, and buyback record Fact: At the end of 2021 the company had roughly 116.0 million shares outstanding; at the end of 2022 roughly 116.9 million; at the end of 2025 roughly 118.4 million, an overall modest increase. But by the end of Q1 2026 common shares had fallen to 116.3 million, because the company repurchased about 2.4 million shares in the quarter. On dividends, the company's annualized common dividend from 2023 to 2026 was $2.16 per share.

Accounting quality and signs of potential manipulation View: In the 10-K, 10-Q, and proxy reviewed, I saw no obvious financial fraud or aggressive-accounting red flags. On the contrary, what truly warrants caution is the "industry noise" inherent to REIT statements—depreciation, asset-sale gains, impairments, straight-line rent, and project capitalization can make a single year's net income either materially depressed or artificially inflated by dispositions. So with KRC, what matters more is cash NOI, FFO/AFFO thinking, and capital-spending discipline, not the P/E ratio.

Owner Earnings

Viewing KRC through a "Buffett-style owner earnings" lens, I try to be conservative rather than chasing flattering figures.

Conservative estimation method: Fact: 2025 net income to common was roughly $276.1 million; depreciation and amortization roughly $354.9 million; capital spending on operating properties and other capital assets roughly $116.0 million; operating cash flow roughly $566.3 million.

Estimate: A simplified, conservative way to write owner earnings is to use operating cash flow minus operating-property capex as an approximation close to AFFO / distributable cash flow. On that basis, 2025 approximate owner earnings ≈ $566.3M − $116.0M = $450.3M. That equates to roughly $3.8 per share.

But I will not simply treat $450 million as long-term distributable cash flow. There are three reasons. First, 2025 occupancy was still low, the leasing recovery is incomplete, and future tenant improvement and leasing costs remain to be spent. Second, the "operating capital spending" on office and lab properties is not necessarily fully equivalent to "maintenance capital spending"; in a weak market, much spending that looks like growth is in fact just to preserve leasing ability. Third, the company is still recycling capital and shifting toward development, so single-year cash flow is affected by sales, construction progress, and working capital swings.

I therefore offer a conservative owner-earnings range better suited to long-term valuation: $380 million–$410 million, or about $3.2–$3.4 per share. This range is roughly below 2025's simplified AFFO-style cash flow, and it looks even more prudent after cross-checking against management's 2026 FFO guidance of $3.49–$3.63 per share. At the current price of $33.42, the market is pricing KRC at roughly 9.8–10.4x the conservative owner earnings I define.

Is free cash flow over the long run above, below, or close to net income? Fact: Take 2023–2025: operating cash flow was $603M / $541M / $566M, clearly above net income to common of $212M / $211M / $276M over the same years. View: This is very common for a REIT and shows the company is not running on pure accounting profit; but one cannot simply say "cash flow is much better than profit, so it is very cheap," because the capital spending needed to preserve leasing ability is real.

Valuation and Margin of Safety

The biggest problem with how the market currently prices KRC is not that it is "outrageously expensive," but that it is "not cheap enough to make me comfortable going overweight."

Discounted Owner Earnings

The intrinsic values below are my estimates, not company guidance and not market consensus. I use an equity cash-flow discount method starting from per-share conservative owner earnings.

Basis for assumptions: Starting owner earnings references 2025 operating cash flow minus operating-property capex, with a haircut combined with the 2026 FFO guidance; the growth rate reflects the pace of office and life science leasing recovery; the discount rate incorporates the structural uncertainty of West Coast office real estate; the terminal growth rate is below that of an excellent growth company, closer to long-term inflation.

Judgment: The current $33.42 roughly implies: for the conservative scenario, no margin of safety; for the neutral scenario, a slight discount; for the optimistic scenario, a clear discount. But I will not use the optimistic scenario as a basis to buy, so my conclusion remains: cheap, but not cheap enough.

Relative Valuation

For a REIT, P/E has weak reference value, so I place more weight on P/FFO, P/B, and EV/EBITDA. On a relative basis, KRC is indeed not expensive.

Note: Prices and market caps are market data from around 2026-05-20; P/FFO, P/B, and EV/EBITDA follow the conventions of the relevant statistics pages, are more useful for cross-sectional comparison, and should not be taken to decimal precision.

View: KRC is clearly cheaper than BXP and VNO, broadly comparable to HIW, but no cheaper than the already deeply punished ARE. In other words, the market does not price KRC as a "flawless asset," but it has not beaten it down to the most pessimistic deep-distress price either. For a value investor, this often means an "attractive but not table-pounding" position.

Asset Value

Fact: At the end of 2025, KRC's shareholders' equity was about $5.421 billion, for a book value per share of about $45.8; the current price of $33.42 is about 0.73x book value.

But View: An office REIT's book value does not equal its realizable value, for three reasons. First, historical cost and the depreciation regime distort true market value. Second, vacancy remains high in markets such as San Francisco Bay Area life science, San Francisco office, and Seattle. Third, in Q1 2026 the company recognized impairment on and sold residential assets held for sale, proving book value is not an inherently reliable cushion.

Estimate: Capitalizing 2025 NOI of $736.2 million roughly, at a cap rate of 7.25%–8.00%, asset value lands in the $9.2–10.2 billion range; netting out debt and other liabilities, equity value falls roughly in the wide range of the low $30s to the low $40s per share. This method is extremely sensitive to the cap rate, so I treat it only as evidence that "the current price has not clearly broken away from the asset floor," not as conclusive proof to buy.

Margin-of-Safety Assessment

Final judgment: The current price is not cheap enough to constitute a sufficient margin of safety. If the stock fell back to the high $20s while debt and occupancy did not deteriorate further, I would be clearly more interested; if the price holds in the low $30s, I would need to see stronger occupancy recovery, positive rent spreads, and a clearer cash-flow repair.

Risks, Comparisons, and Final Judgment

The most important risk is not short-term volatility but permanent loss of capital. I see KRC's major risks falling into the following categories:

Most of the above risks are already reflected in the company's risk disclosures and industry reports, especially remote work, non-renewal of leases, financing conditions, falling asset valuations, development risk, and life science demand swings.

The strongest counter-view can be summarized as: KRC may not be a "misjudged quality landlord" at all, but merely a "holder of high-quality assets in a bad industry that has not yet fully cleared." If office usage density steps down permanently and life science demand recovery is weaker than expected, KRC may keep relying on asset sales to sustain its dividend and development optionality over the next few years; and once core-market cap rates rise, disposition prices come in unfavorably, or the dividend is forced lower, today's seemingly cheap 0.7x P/B and 8–9x P/FFO would be proven falsely cheap.

Which facts would overturn the investment judgment? If the following occur, I would admit that the "watch, not buy" judgment was in fact still too optimistic: First, the stabilized portfolio's leased/occupancy rate excluding KOP2 still cannot return to 80%+ and keep improving over the next 12–24 months; Second, same-store cash NOI is negative for several consecutive years and newly signed cash rents keep deteriorating; Third, asset-sale prices stay clearly below book or market expectations, forcing the company to recognize larger impairments; Fourth, net debt/EBITDA rises clearly above 7x or interest coverage falls below 2x; Fifth, the company is forced to repair its balance sheet through deeply discounted equity issuance or a sharp dividend cut.

Comparison with other opportunities Compared with BXP, the industry's strongest pure Class A office platform, KRC is cheaper but lags BXP in scale, asset distribution, and market influence; compared with ARE, KRC does not trade at as deep a discount as ARE, yet has not escaped the West Coast's twin life science and office headwinds either. Compared with a broad-based index like the S&P 500, KRC's advantages are its high dividend and possible cyclical-repair upside; its disadvantages are a single industry, capital intensity, and a weak long-term moat. Compared with the roughly 4.65% risk-free yield on the U.S. 10-year Treasury, KRC's dividend yield of about 6.5% offers only about 180 basis points more, a risk premium that is not generous for an office REIT. The conclusion is: it is not clearly superior to the index or high-grade bonds enough to take priority claim on core capital.

Investment Checklist

Open Questions and Limitations

This research still has three information gaps: First, the latest top ten tenants and expiry distribution are not fully laid out in the materials obtained; Second, the precise split between maintenance capital spending and value-enhancing capital spending is not directly provided by the company; Third, project-by-project NAV requires more complete supplemental reports and market-by-market cap rate assumptions to estimate precisely. This report therefore uses a conservative approximation for owner earnings and asset value, rather than a refined NAV model.

Final Investment Conclusion

【Final Rating】 Watch

【One-Sentence Investment Thesis】 KRC is a high-quality West Coast office and life science REIT with real asset quality and real cash flow, but industry headwinds, capital intensity, and recovery uncertainty make it look at the current price more like "an attractive tracking candidate" than "a cheap enough long-term overweight."

【Core Bull Case】

• Asset quality is high, the portfolio is concentrated in innovation submarkets, and the company has long-term development and operating capability.

• Cash flow quality is good; from 2023 to 2025 operating cash flow stayed above $500 million, clearly higher than GAAP net income to common.

• Capital allocation is becoming more prudent: selling non-core assets, paying down debt, buying back at low prices, and emphasizing pre-leasing in development.

• The current valuation is not high; P/FFO, P/B, and EV/EBITDA are not expensive relative to most office peers.

• If West Coast Class A office and AI-related demand keep recovering, the company has valuation-repair upside.

【Core Bear Case】

• Industry attractiveness is low; both office and lab space are still digesting post-pandemic structural change and excess supply.

• Overall occupancy remains low, and true pricing power has not yet recovered.

• Capital spending and development investment are large; growth depends on capital rather than easy compounding.

• Leverage is not dangerous, but it is not light either, leaving little room for error in a weak market.

• The current price lacks a thick enough margin of safety, looking "reasonable-to-low" rather than "clearly undervalued."

【Key Assumptions】 For the company to become a worthwhile long-term holding, it must at least meet: the stabilized portfolio (especially excluding KOP2) gradually recovers occupancy; same-store cash NOI is no longer negative over the long run; asset-sale prices prove book value is not seriously overstated; net debt/EBITDA stays in a controllable range; and the dividend does not need to be propped up by sacrificing the balance sheet.

【Fair Buy Price】 $24–28. The basis: under my framework of conservative intrinsic value of $28–32 and neutral intrinsic value of $35–41, I want at least a 20%–30% margin of safety. The current $33.42 does not meet this condition.

【Target Holding Period】 If bought, it should be held with a 5–10 year view, because the investment case depends on asset lease-up, leasing recovery, capital-allocation delivery, and normalization of rates and capital markets, not on a quarter or two of trading swings.

【Expected Annualized Return】 Conservative scenario: 1%–4%; Neutral scenario: 6%–8%; Optimistic scenario: 10%–12%. These are long-term estimates based on the current dividend yield, modest growth, and changes in the valuation range, not short-term price targets.

【Maximum Loss Risk】 If office and life science demand recovery fails, asset-sale prices keep weakening, and the dividend is forced lower, it is not impossible for the stock to return to the $20s or below, and the permanent capital loss relative to the current price could reach 35%–55%. The worst case is not "a short-term price drop" but the simultaneous occurrence of downward asset revaluation + downward cash-flow revision + deteriorating financing conditions.

【Tracking Metrics】 The metrics most worth tracking going forward are: stabilized portfolio occupancy and leased rate; occupancy excluding KOP2; same-store cash NOI; newly signed cash rent spreads; development project pre-leasing rates and capital spending; net debt/EBITDA; interest coverage; asset-disposition cap rates; dividend coverage; and the pace of buybacks and asset sales.

【Signals That Trigger Reassessment】 If any of the following occur, the investment logic must be re-examined: same-store NOI deteriorates consecutively; San Francisco Bay Area/Los Angeles occupancy falls instead of rising; KOP2 lease-up misses expectations; large maturing debt is refinanced at materially higher cost; dividend coverage deteriorates or is cut; large dispositions prove NAV is below expectations; or the company pivots back to aggressive development.

【Final Recommendation】 Put coolly, KRC is not a bad company, nor an obviously cheap bargain. It looks more like an "asset stock with quality, but trapped in a bad industry." If you favor high-quality, low-capital-intensity, wide-moat long-term compounders, KRC does not belong in that category today; if you can accept REIT cycles, know to judge by NOI/AFFO/NAV rather than P/E, and are willing to wait for a thicker margin of safety, it deserves a place on the watch list, but I do not recommend treating it today as an opportunity that must be bought right away.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.